Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose

Abstract

Transfer of the sodium iodide symporter (hNIS) has been proposed as a new principle of cancer gene therapy. Using clinically relevant doses of 131I for the treatment of NIS-expressing prostate carcinoma cells, we investigated the kinetics and the absorbed doses obtained in these tumors. hNIS-expressing cell lines accumulated up to 200 times more iodide when compared to wild-type cells. However, a rapid efflux of the radioactivity (80%) occurred during the first 20 min after replacement of the medium. In rats, the hNIS-expressing tumors accumulated up to 20 times more iodide when compared to contralateral transplanted wild-type tumors. After 24 h and doses of 550, 1200 or 2400 MBq/m2 hNIS-expressing tumors lost 89, 89 and 91% of the initial activity, respectively. Dosimetric calculations showed that 1200 MBq/m2 resulted in 3±0.5 Gy (wild-type tumor 0.15±0.1 Gy) and 2400 MBq/m2 resulted in 3.1±0.9 Gy (wild-type tumor 0.26±0.02 Gy). Although transduction of the hNIS gene induces iodide transport in rat prostate adenocarcinoma a rapid efflux occurs, which leads to a low absorbed dose in genetically modified tumors. With regard to a therapeutic application additional conditions need to be defined leading to iodide trapping.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Marcocci C, Cohen JL, Grollman EF . Effect of actinomycin D on iodide transport in FRTL-5 thyroid cells. Endocrinology 1984; 115: 2123–2132.

    Article  CAS  Google Scholar 

  2. Weiss SJ, Philp NJ, Grollman EF . Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984; 114: 1090–1098.

    Article  CAS  Google Scholar 

  3. Paire A, Bernier-Valentin F, Selmi-Ruby S, Rousset B . Characterization of the rat thyroid iodide transporter using anti-peptide antibodies. J Biol Chem 1997; 272: 18245–18249.

    Article  CAS  Google Scholar 

  4. Nakamura Y, Ohtaki S, Yamazaki I . Molecular mechanism of iodide transport by thyroid plasmalemmal vesicles: cooperative sodium activation and asymmetrical affinities for the ions on the outside and inside of the vesicles. J Biochem 1988; 104: 544–549.

    Article  CAS  Google Scholar 

  5. Nakamura Y, Kotani T, Ohtaki S . Transcellular ioide transport and iodination on the apical plasma membrane by mono-layer porcine thyroid cells cultured on collagen-coated fibers. J Endocrinol 1990; 126: 275–281.

    Article  CAS  Google Scholar 

  6. Smanik PA et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996; 226: 339–345.

    Article  CAS  Google Scholar 

  7. Dai G, Levy O, Carrasco N . Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458–460.

    Article  CAS  Google Scholar 

  8. Boland A et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484–3492.

    CAS  Google Scholar 

  9. Boland A et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 2002; 12: 19–26.

    Article  CAS  Google Scholar 

  10. Carlin S et al. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Ther 2000; 7: 1529–1536.

    Article  CAS  Google Scholar 

  11. Cho JY et al. Expression and activity of human Na+/I symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 2000; 7: 740–749.

    Article  CAS  Google Scholar 

  12. Haberkorn U et al. Transfer of the human sodium iodide symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001; 42: 317–325.

    CAS  Google Scholar 

  13. La Perle KMD et al. In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate 2002; 50: 170–178.

    Article  CAS  Google Scholar 

  14. Mandell RB, Mandell LZ, Link CJ . Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59: 661–668.

    CAS  Google Scholar 

  15. Nakamoto Y et al. Establishment and characterization of a breast cancer cell line expressing Na+/I symporters for radioiodide concentrator gene therapy. J Nucl Med 2000; 41: 1898–1904.

    CAS  PubMed  Google Scholar 

  16. Shimura H et al. Iodide uptake and experimental 131J therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I symporter gene. Endocrinology 1997; 138: 4493–4496.

    Article  CAS  Google Scholar 

  17. Smit JW et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 2000; 10: 939–943.

    Article  CAS  Google Scholar 

  18. Smit JWA et al. Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 2002; 87: 1247–1253.

    Article  CAS  Google Scholar 

  19. Spitzweg C et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60: 6526–6530.

    CAS  Google Scholar 

  20. Spitzweg C et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001; 8: 1524–1531.

    Article  CAS  Google Scholar 

  21. Huang M et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001; 8: 612–618.

    Article  CAS  Google Scholar 

  22. Berman M, Hoff E, Barandes M . Iodine kinetics in man: a model. J Clin Endocrinol Metab 1968; 28: 1–14.

    Article  CAS  Google Scholar 

  23. Freireich EJ et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Rep 1966; 50: 219–244.

    CAS  Google Scholar 

  24. Maxon HR et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309: 937–941.

    Article  CAS  Google Scholar 

  25. Haberkorn U et al. Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur J Nucl Med 2001; 28: 633–638.

    Article  CAS  Google Scholar 

  26. Koong S et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 912–916.

    CAS  PubMed  Google Scholar 

  27. Urabe M et al. Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology 1991; 129: 807–814.

    Article  CAS  Google Scholar 

  28. Lazarus JH . The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998; 8: 909–913.

    Article  CAS  Google Scholar 

  29. Sedvall G, Jonsson B, Petterson U, Levin K . Effects of lithium salts on plasma protein bound iodine and uptake of 131I in thyroid gland of man and rat. Life Sci 1968; 7: 1257–1264.

    Article  CAS  Google Scholar 

  30. Temple R, Berman M, Robbins J, Wolff J . The use of lithium in the treatment of thyrotoxicosis. J Clin Invest 1972; 51: 2746–2756.

    Article  CAS  Google Scholar 

  31. Gershengorn MC, Izumi M, Robbins J . Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma. J Clin Endocrinol Metab 1976; 42: 105–111.

    Article  CAS  Google Scholar 

  32. Sieger S et al. Tumour specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med: in press.

  33. Dadachova E et al. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002; 29: 13–18.

    Article  CAS  Google Scholar 

  34. Petrich T et al. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium iodide symporter. Eur J Nucl Med 2002; 29: 842–854.

    Article  CAS  Google Scholar 

  35. Haberkorn U, Altmann A, Eisenhut M . Functional genomics and proteomics – the role of nuclear medicine. Eur J Nucl Med 2002; 29: 115–132.

    Article  CAS  Google Scholar 

  36. Pear WS, Nolan GP, Scott ML, Baltimorre D . Production of high titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392–8396.

    Article  CAS  Google Scholar 

  37. Kinscherf R et al. Induction of manganese superoxide dismutase by oxidized-LDL – its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits. FASEB J 1997b; 11: 1317–1328.

    Article  CAS  Google Scholar 

  38. Stabin M . MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538–546.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Mrs Irmgard Preugschat-Gumprecht and Silke Vorwald for expert assistance with immunocytochemistry and R Kühnlein for his help in performing the animal experiments. We also thank N Morgenthaler and J Struck (BRAHMS Diagnostics, Berlin, Germany) for supplying hNIS antibodies. This study was supported by a grant from the ‘Tumorzentrum Heidelberg/Mannheim’.

This article is dedicated to Harald zur Hausen on the occasion of his retirement as head of the German Cancer Research Center with gratitude and appreciation for 20 years of leadership.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haberkorn, U., Kinscherf, R., Kissel, M. et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 10, 774–780 (2003). https://doi.org/10.1038/sj.gt.3301943

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301943

Keywords

This article is cited by

Search

Quick links